

21 Settembre 2026, Milano

- **TITOLO:** Melanoma Bridge
- **Data di svolgimento:** 2-3 Dicembre 2026
- **Sede di svolgimento dell'Evento:** Royal Continental Hotel (Via Partenope 38-42 – 80121 Napoli)
- **Tipologia:** RESIDENZIALE
- **ID Provider:** 596
- **Obiettivo formativo:** 18. Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere
- **Nome Segreteria Organizzativa:** VIVENKO Srl Società Benefit
- **Lingua:** Inglese – non prevista traduzione simultanea

RAZIONALE SCIENTIFICO

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immunoevasion strategies has resulted in different approaches to target and harness the immune response.

Approval of new immune and target therapies has further improved outcomes for patients with advanced melanoma. The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities.

This year latest findings in melanoma research and advances on topics of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the dedicated sessions, focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.

Then, the “Great Debate” sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view.



PROGRAMMA SCIENTIFICO

\\attività.non.inclusa.nell'accREDITAMENTO.ECM

2 Dicembre 2026

09.15 Introduction and objectives, Paolo A. Ascierto

SESSION 1 - MORE TRANSLATIONAL RESEARCH IN MELANOMA

Chairpersons: Christian Blank, Lisa Villabona

- 09.20 Translational data from personalized cancer vaccination trials, Ryan Sullivan
- 09.35 Metabolism, Bradley Isaac Reinfeld
- 09.50 Harnessing CD26hi T cells to mediate potent activity against melanoma, Chrystal M. Paulos
- 10.05 Harnessing macrophages for anti-cancer therapy, Jennifer Guerriero
- 10.20 TME, Charles Swanton
- 10.35 Spatial Trans-Criptomics, Florian Rambow
- 10.50 Genomic approaches, Tomas Kirchhoff
- 11.05 Discussion on More Translational Research in Melanoma

11.30 Coffee Break**

11.45 SYMPOSIUM - The key role of adjuvant therapy in Melanoma

Chair: Paolo A. Ascierto

Paolo A. Ascierto, Sapna Patel

GREAT DEBATE

Chairpersons: Paolo A. Ascierto, Corrado Caracò, Igor Puzanov

- 12.35 Prediction of therapy outcome: Biological markers VS AI predictive algorithm, Christian Blank
VS Georgina Long
- 13.00 Use of ctDNA monitoring to guide clinical decisions, ready for primetime now: YES or NO
Reinhard Dummer VS Dirk Schadendorf
- 13.25 Lunch**

SESSION 2 – WHAT HAVE WE LEARNED FROM...

Chairpersons: Igor Puzanov, Corrado Caracò

- 14.15 ...failed studies? Jeffrey Sosman
- 14.30 ...studies ongoing that haven't read out? Olivier Michielin
- 14.45 ...clinical gaps in Melanoma? Omid Hamid
- 15.00 What are we learning with PD-L1/IDO vaccination? James Smithy
- 15.15 ...using a common control arm: opportunities and challenges, Ryan Sullivan
- 15.30 Discussion on What have we learned from...?



- 15.50 SYMPOSIUM Target Therapy in Metastatic Melanoma
Chairperson: Paolo A. Ascierto
Paolo A. Ascierto, Reinhard Dummer
- 16.40 SYMPOSIUM Bridging evidence and experience in Metastatic Uveal Melanoma
Chairperson: Paolo A. Ascierto
Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial, Paul Nathan
Translating evidence into practice: international experience with tebentafusp in metastatic uveal melanoma, Ester Simeone

GREAT DEBATE

Chairpersons: Paolo A. Ascierto, Corrado Caracò, Igor Puzanov, Alessandro Testori

- 17.30 TIL: frontline vs second line, Allison Betof vs Igor Puzanov
17.55 Reality Check of Benefits: all Stages vs Advanced Stages, Alexander Eggermont vs Michael Postow

3 Dicembre 2026

SESSION 3 - EMERGENT STRATEGIES

Chairperson: Giuseppe Palmieri

- 09.15 Brain Metastases, Hussein Tawbi
09.30 Acral Melanoma, Mitch Levesque
09.45 Mucosal Melanoma, Alex Shoushtari
10.00 Neoadjuvant Study: IPI-NIVO vs NIVO-RELA, Janice Mehnert
10.15 Toxicities management, Douglas Johnson
10.30 Engineered TILs, Olivier Michielin
10.45 Discussion on Emergent Strategies
- 11.00 Coffee Break**
- 11.15 Novel MAPK Inhibitor, Roger Lo
11.30 Do we need New Staging? Jeffrey Gershenwald
11.45 Not all Immune Checkpoints are created equal: an update on IDO, Marc S. Ernstoff
12.00 Injectable Therapies, Danielle Bello
12.15 Discussion on Emergent Strategies
- 12.30 LECTURE - Advancing Cancer Treatment with mRNA: The Evolving Role of Immune Modulation
Allison Betof, Hussein A. Tawbi



GREAT DEBATE

Chairpersons: Paolo A. Ascierto, Corrado Caracò, Igor Puzanov

13.00 Spatial Biology: YES or NO, Carlo Bifulco VS Jerome Galon

13.25 Quality of Life vs Efficacy, Omid Hamid VS Paul Nathan

13.50 Putting it all together: Practical Considerations for Monday Clinic, Igor Puzanov

14.05 Conclusion

QUALIFICHE PROFESSIONALI E SCIENTIFICHE DEL RESPONSABILE SCIENTIFICO E DEI RELATORI:

COGNOME	NOME	LAUREA	SPECIALIZZAZIONE	AFFILIAZIONE
Ascierto	Paolo Antonio	Medicina e Chirurgia	Oncologia	Full professor of Oncology; Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department; University of Naples Federico II; National Cancer Institute "Fondazione G. Pascale"; Naples, Italy
Bello	Danielle	Medicina e Chirurgia	Chirurgia	Assistant Attending Surgeon; Memorial Sloan Kettering Cancer Center; New York, NY, USA
Betof	Allison	Medicina e Chirurgia	Oncologia	Assistant Professor of Medicine (Oncology); Mark and Mary Stevens Endowed Scholar in Melanoma, Director, Melanoma Program, Director, Solid Tumor Cellular Therapy, Leader, Melanoma & Cutaneous Oncology Clinical Research Group Stanford University School of Medicine; Stanford Cancer Center; Standford, California, US
Bifulco	Carlo	Medicina e Chirurgia	Anatomia Patologica	Medical Director of Oncological Molecular Pathology and pathology Informatics, Providence Oregon Regional Laboratory, Director of Translational Molecular Pathology; Earle A. Chiles Research Institute, Providence Cancer Institute; Providence, Oregon, US
Blank	Christian	Medicina e Chirurgia	Oncologia, Ematologia	Director of Sarcoma and Melanoma Program; Medical Oncology and Research Group Leader Tumor Immunology; IEO, European Oncology Institut; Netherlands Cancer Institute; Milan, Italy; Amsterdam, The Netherlands
Caracò	Corrado	Medicina e Chirurgia	Oncologia, Chirurgia Generale	Department Director of Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck; National Cancer Institute "Fondazione G. Pascale"; Naples, Italy
Dummer	Reinhard	Medicina e Chirurgia	Dermatologia	Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center; University of Zurich Hospital, Department of Dermatology; Zurich, Switzerland



Eggermont	Alexander M.M.	Medicina e Chirurgia	Chirurgia Generale	Chief Scientific Officer, Board of Directors Professor Surgical Oncology; Princess Máxima Center for pediatric oncology; Utrecht, The Netherlands; Bethesda, Maryland, USA
Ernstoff	Marc S.	Medicina e Chirurgia	Medicina Interna; Oncologia	Branch Chief ImmunoOncology (IOB), Development Therapeutics Program Cancer therapy and Diagnosis Division; NCI (National Cancer Institute); NIH (National Institutes of Health)
Galon	Jerome	Medicina e Chirurgia	Oncologia	Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team; Cordeliers Research Center; Paris, France
Gershenwald	Jeffrey E.	Medicina e Chirurgia	Chirurgia oncologica	Professor, Department of Surgical Oncology, Division of Surgery; The University of Texas, MD Anderson Cancer Center; Houston, Texas, US
Guerriero	Jennifer	Biochimica	Biologia molecolare e cellulare	Assistant Professor; Director Breast Tumor Immunology Lab; Brigham and Women's Hospital; Dana-Farber Cancer Institute; Boston, Massachusetts, US
Hamid	Omid	Medicina e Chirurgia	Oncologia	Director, Clinical Research and Immunotherapy; The Angeles Clinic and Research Institute; Los Angeles, California, US
Kirchhoff	Tomas	Medicina e Chirurgia	Oncologia	Associate Professor, Department of Population Health; Perlmutter Cancer Center, New York University School of Medicine; New York, USA
Johnson	Douglas B.	Medicina e Chirurgia	Medicina Interna, Oncologia	Assistant Professor of Medicine, Clinical Director of Melanoma, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center; Nashville, Tennessee, US
Levesque	Mitchell	Medicina e Chirurgia	Dermatologia	associate professor of translational dermatology, Scientific Department Leader in the Department of Dermatology; University Hospital Zurich, Svizzera
Lo	Roger	Medicina e Chirurgia	Dermatologia	Professor of Medicine, Molecular and Medical Pharmacology; David Geffen School of Medicine, UCLA; Los Angeles, California, US
Long	Georgina V.	Medicina e chirurgia	Oncologia	Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital; Melanoma Institute Australia and The University of Sydney; Australia
Mehnert	Janice	Medicina e Chirurgia	Medicina Interna; Oncologia	Professor, Department of Medicine at Director, Melanoma Medical Oncology Program, NYU Grossman School of Medicine, Perlmutter Cancer Center Associate Director, Clinical Research; New York, New York, USA
Michielin	Olivier	Medicina e Chirurgia	Oncologia	Service d'oncologie de précision et chef du Département d'oncologie des HUG, Hôpitaux Universitaires Geneve, Suisse
Nathan	Paul	Medicina e Chirurgia	Oncologia	Consultant Medical Oncologist and Honorary Professor of Oncology, Honorary Consultant Medical Oncologist; Mount Vernon Cancer Centre,



				University College London, University College London Hospitals
Palmieri	Giuseppe	Medicina e Chirurgia	Oncologia	Medical Oncologist Investigator at the Institute of Biomolecular Chemistry of the National Research Council (ICB-CNR); Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy
Paulos	Chrystal M.	Biochimica	Immunologia	Director of translational research in cutaneous malignancies; Associate Professor, Department of Surgery, Department of Microbiology and Immunology; Winship Cancer Institute of Emory University; Emory University School of Medicine
Patel	Sapna	Medicina e Chirurgia	Oncologia	Director of Cutaneous Oncology Professor of Medicine and Ophthalmology University of Colorado Chair, SWOG Melanoma Committee Aurora - CO- USA
Postow	Michael A.	Medicina e Chirurgia	Oncologia	Chief, Melanoma Service; Memorial Sloan Kettering Cancer Center; New York, NY, US
Puzanov	Igor	Medicina e Chirurgia	Oncologia	Professor of Medicine and Oncology, Director Early Phase Clinical Trials Program, Co-Leader Experimental Therapeutics Program, Chief Melanoma Section; Department of Medicine, Rosewell Park Comprehensive Cancer Center; Buffalo, New York, US
Rambow	Florian	Biotechnologie	Biologia Molecolare	Director of Applied Computational Cancer Research; University Hospital Essen; Germany
Reinfeld	Bradley Isaac	Medicina e Chirurgia	Oncologia	Medical Oncology Fellow; Memorial Sloan Kettering Cancer Center; New York, NY, USA
Schadendorf	Dirk	Medicina e Chirurgia	Dermatologia	Director of Clinic for Dermatology; University Hospital Essen, Germany
Shoushtari	Alexander	Medicina e Chirurgia	Oncologia	Assistant Attending Physician; Memorial Sloan Kettering Cancer Center; New York, NY, US
Simeone	Ester	Medicina e Chirurgia	Oncologia	Dirigente Medico; National Cancer Institute "Fondazione G. Pascale"; Naples, Italy
Smithy	James	Medicina e Chirurgia	Oncologia	Melanoma Oncologist & Cellular Therapist, Assistant Attending Physician; Memorial Sloan Kettering Cancer Center; New York, NY, US
Sosman	Jeffrey	Medicina e Chirurgia	Oncologia	Professor of Medicine; Director, Melanoma program; Director, Faculty Development; Co-Leader, Translational Research in Solid Tumors; Robert H. Lurie Comprehensive Cancer Center, Northwestern University; Evanston, Illinois, US
Sullivan	Ryan	Medicina e Chirurgia	Oncologia	Associate Professor, Medicine, Associate Professor, Hematology/Oncology, Harvard Medical School; Massachusetts General Hospital; Boston, Massachusetts; US
Swanton	Charles	Medicina e Chirurgia	Oncologia	Clinical Director of Cancer Evolution And Genome Instability Laboratory; Francis Crick Institute; London, UK



Tawbi	Hussein	Medicina e Chirurgia	Oncologia; Medicina Interna	Professor, Deputy Chair and Director of Personalized Cancer Therapy, Department of Melanoma Medical Oncology, Division of Cancer Medicine; Co-Director, MD Anderson Brain Metastasis Clinic; The University of Texas MD Anderson Cancer Center; Houston, Texas, US
Testori	Alessandro	Medicina e Chirurgia	Chirurgia Generale	Direttore Dermato-Oncologia; Istituto Image; Milan, Italy
Villabona	Lisa	Medicina e Chirurgia	Oncologia	Professor of Clinical Oncology; Department of Oncology-Pathology, Karolinska Institute; Stockholm, Sweden

Responsabile Scientifico dell'evento: Paolo A. Ascierto | Professore Ordinario di Oncologia, Università degli Studi di Napoli Federico II; Direttore S.C. Oncologia Sperimentale, Melanoma, Immunoterapia e Terapie Innovative, Istituto Nazionale dei Tumori IRCCS Fondazione G. Pascale, Napoli

DESTINATARI:

- **Numero partecipanti:** 201
- **Destinatari dell'attività formativa:** **Farmacista** (Farmacista pubblico del SSN; Farmacia ospedaliera; Farmacista di altro settore); **Medico chirurgo** (Allergologia ed immunologia clinica; dermatologia e venereologia; ematologia; gastroenterologia; Malattie dell'apparato respiratorio; medicina interna; nefrologia; neurologia; oftalmologia, oncologia; radioterapia; chirurgia generale; chirurgia plastica e ricostruttiva; ginecologia e ostetricia; urologia; anatomia patologica; farmacologia e tossicologia clinica; laboratorio di genetica medica; medicina nucleare; patologia clinica (laboratorio di analisi chimico-cliniche e microbiologia); radiodiagnostica; igiene, epidemiologia e sanità pubblica; medicina generale (medici di famiglia); scienza dell'alimentazione e dietetica; cure palliative.

ACRONIMI

AI: Artificial Intelligence

CD26hi: Cluster of Differentiation 26 High

CTLA-4: Cytotoxic T-Lymphocyte Antigen 4

ctDNA: Circulating Tumor DeoxyriboNucleic Acid

IDO: Indoleamine 2,3-dioxygenase

MRA: Melanoma Research Alliance

PDL 1: Programmed Death-Ligand 1

TIL: Tumor-Infiltrating Lymphocyte

TCR: T Cell Receptor

TME: Tumor MicroEnvironment

